The Eventful Liposomal Formulation Procedural

By Kristen Baird


Among the major areas of care fixated by people is their health. As such, advances in medicines are duly welcome and highly appreciated. Progress in research of various diseases and development of drugs to help curb them is always a good indicator. One such aspect of progress has been noted in liposomal formulation.

The process of this formulation was discovered 50 years ago. It came about as a solution to a problem of drugs taken orally being exhausted and digested before reaching the intended target areas. The liposomal way was deemed best suited since it was a favorable carrier to both hydrophilic and hydrophobic drugs.

The simplicity of the liposomes' structural composition is key to its performance. They are made up of an aqueous solution which is engulfed in a strengthened mesh of either natural or synthetic phospholipids. The advantage of this is that it can fuse non-reactively with both hydrophilic and hydrophobic drugs, each attaching to the element it does not react to.

The main advantage of using liposomes comes from its core structure. The procedure of formation is key to this. They are formed when a specific heat level is exposed to phospholipids immersed in water. This provides the right atmosphere for formation of liposomes. The physiochemical composition should then be deduced so as to enable the liposome act as an appropriate carrier for an appropriate drug - given its composition to avoid any reactions.

Advances such as these have led to further progress in the medical field. The most famous being development of Doxorubicin, a form of anthracycline. This is a drug that was developed to curb the spread of cancer. It does this in two stages, first, by inserting base stains of DNA and RNA molecules which inhibits replication of cells. The second phase is inhibition of an enzyme known as topoisomerase II, which serves the same purpose of inhibition of cellular growth.

It is due to advances in the medical field that control of many diseases is not a reality. Terminal illnesses previously viewed as a death sentence are now controllable and some even treatable. Research on cancer and liposomes has led to development of anti-cancer drugs an their carriers. The development has brought about continuing tests and usage of doxorubicin, paclitaxel, cisplatin, lipoplatin, aroplatin among others.

Some diseases which were considered deadly can now be mitigated via vaccines. Research in the field of liposomes has led to development of several vaccines which can now be actively used as preventative medicine. Most however are still undergoing rigorous testing. Some of the vaccines created include Inflexal V against influenza, Epaxal for Hepatitis, and Stimuvax for cancer.

The use of liposomes as a carrier for dietary supplements is a newer idea that I undergoing further research. The idea is to use the same technique as the currently successful targeted drug delivery to deliver various supplements taken orally to specific areas in the body. This is however still undergoing research and testing. The use of liposomes in creation of various drugs and vaccines has led to a huge leap in terms of drug research and development. The process of the formulation has thus been lauded as wielding enormous potential for development of better medical solutions for a lot of persistent medical conditions.




About the Author:



No comments :

Post a Comment